Introduction & Research Applications
Synedica Retatrutide 40mg Injection Pen Kit provides a research-format presentation of retatrutide, also identified as LY3437943. Retatrutide is an investigational peptide studied for activity across three receptor pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. A published Phase 2 study in the New England Journal of Medicine describes retatrutide as a single-molecule triple receptor agonist.
For laboratory researchers, the Retatrutide 40mg Injection Pen Kit may be relevant to research involving receptor pharmacology, metabolic signalling, endocrine pathways and comparative investigation of multi-receptor agonists. Researchers can also review the developer’s current scientific information through Eli Lilly’s Retatrutide research information.
Researchers can explore related materials through the Synedica Health UK Research Peptides collection and Metabolic Research Peptides category.
Technical Specifications & Purity
The Retatrutide 40mg Injection Pen Kit contains a stated 40mg quantity of retatrutide in an integrated pen-format presentation. The compound identifier is LY3437943, with retatrutide scientifically characterised as a GIP, GLP-1 and glucagon receptor agonist.
Technical specifications:
- Compound: Retatrutide / LY3437943
- Quantity: 40mg
- Presentation: Injection pen kit
- Research classification: Investigational research compound
- Purity: ≥99.0% HPLC, subject to applicable batch COA verification
Researchers should verify the exact purity result, analytical method, batch number and corresponding Certificate of Analysis (COA) supplied with the applicable lot before using analytical specifications in laboratory records.
For additional laboratory materials, explore the Synedica Health UK Research Peptide Collection.
Storage, Reconstitution & Handling Protocols
The Retatrutide 40mg Injection Pen Kit should be stored and handled according to the manufacturer’s current product documentation and applicable batch instructions. Researchers should always follow the storage conditions supplied with the specific product rather than relying on generic peptide-storage recommendations.
Maintain the product in appropriate packaging and minimise unnecessary exposure to environmental conditions that could affect material integrity. Laboratory personnel should document receipt, storage and handling in accordance with established research protocols.
Any laboratory preparation or reconstitution should be performed only by appropriately trained personnel using validated institutional procedures. This product listing does not provide human or veterinary administration instructions.
Researchers looking for additional laboratory materials can browse the Synedica Metabolic Research Peptides category.
Quality Assurance & Regulatory Compliance
Quality assurance should be based on traceable batch documentation. Researchers should record the product name, batch or lot number and applicable analytical documentation when receiving Retatrutide 40mg Injection Pen Kit.
Where supplied, HPLC analysis and the corresponding Certificate of Analysis can be used to document the analytical characteristics of the applicable batch. Researchers should evaluate the COA associated with their specific lot rather than automatically applying specifications from another batch.
Retatrutide remains an investigational compound. Eli Lilly’s current information states that retatrutide is still being studied in clinical trials and is not yet available for public use. Researchers can review the manufacturer’s current information in What to Know About Retatrutide.
For additional products and laboratory materials, visit the Synedica Health UK Research Peptide Catalogue.
FOR IN VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR CONSUMPTION. NOT FOR DIAGNOSIS, TREATMENT, CURE OR PREVENTION OF ANY DISEASE.
Frequently Asked Questions
What is Retatrutide 40mg Injection Pen Kit?
Retatrutide 40mg Injection Pen Kit is a research-format presentation containing 40mg of retatrutide (LY3437943), an investigational triple receptor agonist studied in controlled research.
What is retatrutide also called?
Retatrutide is also identified by the development code LY3437943.
What receptors does retatrutide target?
Research describes retatrutide as an agonist of the GIP, GLP-1 and glucagon receptors. The mechanism is described in the published NEJM retatrutide study.
Is retatrutide approved for general use?
Retatrutide is an investigational compound and should not be marketed on this product page as an approved medicine. Current information from Eli Lilly identifies retatrutide as an investigational molecule undergoing clinical development.
Is Retatrutide 40mg Injection Pen Kit for human use?
No. This research product is intended strictly for controlled in-vitro research and is not intended for human or veterinary administration.
What purity is available for Retatrutide 40mg?
The stated product specification is ≥99.0% HPLC, subject to confirmation against the Certificate of Analysis for the applicable batch.
How should Retatrutide 40mg be stored?
Researchers should follow the storage conditions supplied with the specific product and batch documentation. The applicable manufacturer’s instructions should take precedence over generic storage recommendations.
Where can researchers find related research peptides?
Researchers can browse the Synedica Health UK Research Peptides and Metabolic Research Peptides categories for related research materials.








Reviews
There are no reviews yet.